Capping circular mRNA in a new way ICIT builds on the promise of circular mRNAs, a new generation of mRNA treatments known for their stability and reduced inflammatory effects compared to ...
Venice, Italy-based Officinae Bio's proprietary digital platform accelerates the prototyping of mRNA drug candidates, enabling the rapid testing of diverse combinations of capping analogs ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Hosted on MSN24d
Circular mRNA produces 200 times more protein, enhancing precision therapy potentialAbe's team overcame this hurdle by introducing a cap structure into the circular mRNA itself. This internal cap structure triggers translation initiation, bypassing the need for IRES sequences ...
With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and ...
MODERNA INC (MRNA) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the stock’s valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback